Malignant Bone Marrow Neoplasm
NCI Definition: Malignant neoplasms that either originate from the bone marrow (e.g. myeloid leukemias) or involve the bone marrow as secondary-metastatic tumors (e.g. metastatic carcinomas to the bone marrow). --2003 
Malignant bone marrow neoplasms most frequently harbor alterations in TET2, ASXL1, DNMT3A, TP53, and JAK2 .
JAK2 Mutation, JAK2 V617F, JAK2 Exon 14 Mutation, DNMT3A Mutation, and TP53 Mutation are the most common alterations in malignant bone marrow neoplasm .
There are 2 clinical trials for malignant bone marrow neoplasm, of which 2 are open and 0 are completed or closed. Of the trials that contain malignant bone marrow neoplasm as an inclusion criterion, 2 are phase 1 (2 open).
Mgd013 and liposome-encapsulated daunorubicin-cytarabine are the most common interventions in malignant bone marrow neoplasm clinical trials.
Significant Genes in Malignant Bone Marrow Neoplasm
ERBB2 is altered in 0.55% of malignant bone marrow neoplasm patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant bone marrow neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant bone marrow neoplasm as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.